DRUG · Mapped RxNorm record
Trastuzumab
Normalized identity: trastuzumab View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years
NCT01810393
Study summary
ClinicalTrials.govA Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Advertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
TrastuzumabDRUG · verified · RxNorm: trastuzumab
Sponsors & collaborators
Hoffmann-La Rochelead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01810393 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.